Corporate Profile talks to CEO of Pluristem about its New Product for Acute Radiation
Corporate Profile talks to CEO of Pluristem about its New Product for Acute Radiation
Видео Corporate Profile talks to CEO of Pluristem about its New Product for Acute Radiation канала CorporateProfile
Видео Corporate Profile talks to CEO of Pluristem about its New Product for Acute Radiation канала CorporateProfile
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
U.S. Navy Approves Start of CEL-SCI's Phase I Trial for HIV/HPV Co-Infected PatientsCPreports 12/3/12 - Greece Debt Buyback, Delta wants Virgin, Vampire in Serbia on the LooseCorporateProfile.com interviews Nic Toms, Decision Point Systems (DNPI)Pluristem's Manufacturing Facility Approved by European Auditors for Phase III TrialsWhite House Sexual Misconduct Scandal, China Astronauts, NYC Diabetes EpidemicNews 2/19/13 - Magnolia Bakery Mice Infestation, Maker's Mark Scandal, Burgerking's Twitter HackedInterview w/ West Australian Distilling Company Co-Founder Andy NyeKitov Reports KIT-302 Has Beneficial Effects on Kidney FunctionDaby Carreras, of Spartan Capital Securities, speaks about The Wall Street Run and Heart WalkCorporate Profile interviews Celebrity Photographer Michael Letterlough Jr.Bluesphere Announces Start of 5.2 MW Waste-to-Energy Project in Charlotte, North CarolinaCory Monteith Overdose, North Korea Ships Missiles in Sugar, & Woman Struck by Lightning in StoreUniversity of Minnesota Masonic Cancer Center Joins CEL-SCI’s Phase III Head & Neck Cancer TrialWize Pharma Hopes To Shake Up $3.7B RX Eye Drop MarketSmartMetric to Launch World's First Bitcoin Card With Biometric Fingerprint ProtectionFirst Bitcoins Seized by Feds, Cuba backs Snowden Asylum, Andy Murray makes Wimbledon 2013 HistoryCEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Cancer Trial into the UKCan-Fite Issued Japanese Patent for Treatment of Liver RegenerationLabStyle Innov. Successful User Performance Evaluation Study to Support 510(k) ApplicationUnited Therapeutics Advances to Second Cohort in Phase I Trial of PSTI's PLX-PAD Cells